KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Receivables (2020 - 2025)

Historic Receivables for Esperion Therapeutics (ESPR) over the last 6 years, with Q3 2025 value amounting to $119.0 million.

  • Esperion Therapeutics' Receivables rose 7542.46% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 7542.46%. This contributed to the annual value of $80.1 million for FY2024, which is 6526.17% up from last year.
  • Per Esperion Therapeutics' latest filing, its Receivables stood at $119.0 million for Q3 2025, which was up 7542.46% from $107.7 million recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Receivables ranged from a high of $119.0 million in Q3 2025 and a low of $21.7 million during Q3 2021
  • Over the past 5 years, Esperion Therapeutics' median Receivables value was $40.8 million (recorded in 2023), while the average stood at $49.8 million.
  • In the last 5 years, Esperion Therapeutics' Receivables soared by 8513.08% in 2021 and then soared by 1285.55% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Receivables (Quarter) stood at $22.9 million in 2021, then skyrocketed by 47.07% to $33.7 million in 2022, then soared by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then skyrocketed by 48.46% to $119.0 million in 2025.
  • Its last three reported values are $119.0 million in Q3 2025, $107.7 million for Q2 2025, and $81.3 million during Q1 2025.